BioSpace News Archive

Ambrx Inc. today announced the appointment of Gary Yeung, CFA, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Yeung brings extensive leadership experience in raising capital, building biotech companies, and leading organizations to develop novel therapeutics

Collaboration seeks to develop next-generation viral vectors for gene therapy and gene editing applications in liver and two other tissues. Program brings new levels of momentum to LogicBio as company plans for initiation of enrollment of SUNRISE Phase I/II clinical trial in treatment of methylmalonic acidemia (MMA) and other milestones.

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA’s total capital raised to nearly $109 million.

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the promotion of Michael Goldstein, MD, MBA, to the newly created position of President, Ophthalmology. Dr. Goldstein will continue to report to Antony Mattessich, Ocular’s President and Chief Executive Officer

Spectrum Solutions, LLC announced it has partnered with Steribottle to provide its innovative SDNA-1000 Saliva Collection Device for the COVID-19 population testing directive in the UK.

Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the RISE study – The Risperidone Subcutaneous Extended-Release Study), a Phase 3 clinical trial designed to evaluate the efficacy of TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) as a treatment for patients with schizophrenia.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Corinne Le Goff, Pharm.D., MBA, will join Moderna as Chief Commercial Officer effective Tuesday, January 19, 2021.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco , CEO of CNS Pharmaceuticals, will present at the virtual H.C. Wainwright BioC

Vividion Therapeutics, Inc., a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that seasoned financial executive Patricia “Patty” Allen has joined Vividion as acting chief financial officer.

LG Chem announced today that its Sabin-Inactivated Polio Vaccine (Sabin-IPV) Eupolio™ received World Health Organization (WHO) prequalification effective December 21 st , 2020, enabling it to be supplied globally as early as this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210107005307/en/ LG Chem Sabin-Inactivated Polio Vaccine (Sabin-IPV) E